Posted by Michael Wonder on 06 Jun 2023
US FDA approves new indication for Merck’s Prevymis (letermovir) for prevention of cytomegalovirus disease in high-risk adult kidney transplant recipients
6 June 2023 - Prevymis now approved for cytomegalovirus (CMV) prophylaxis after kidney transplant in donor CMV seropositive/recipient CMV seronegative patients.
Merck today announced the US FDA has approved a new indication for Prevymis (letermovir) for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative) following a priority review.
